Patents by Inventor Xuejing YAO

Xuejing YAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12372504
    Abstract: The present disclosure relates to a method for detecting TCEP content in ADC by LC-MS/MS. The ADC samples are derivatized by Ellman reaction, and then the TCEP content is measured by LC-MS/MS. This method can exclude the interference caused by the substances that may react with Ellman in complex ADC samples, which provides with no need for sample pretreatment, and with strong specificity.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: July 29, 2025
    Assignee: REMEGEN CO., LTD.
    Inventors: Xuejing Yao, Li Wang, Wenlong Sun, Guiping Qi
  • Publication number: 20240201147
    Abstract: The present disclosure relates to a method for detecting TCEP content in ADC by LC-MS/MS. The ADC samples are derivatized by Ellman reaction, and then the TCEP content is measured by LC-MS/MS. This method can exclude the interference caused by the substances that may react with Ellman in complex ADC samples, which provides with no need for sample pretreatment, and with strong specificity.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 20, 2024
    Inventors: Xuejing YAO, Li WANG, Wenlong SUN, Guiping QI
  • Publication number: 20240183827
    Abstract: The present disclosure relates to a method for detecting DTPA content in ADC by LC-MS/MS. The samples are derivatized with Fe3+ under a weak alkaline derivatization condition, and a weak alkaline mobile phase is used, without need for addition of ion-pair reagents. This method has the characteristics of high efficiency, high stability and strong durability, and can well make up for the defects of few DTPA detection methods and complicated operations in the prior art.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 6, 2024
    Inventors: Xuejing YAO, Fangfang SUN, Wenlong SUN, Guiping QI
  • Publication number: 20240165253
    Abstract: The present disclosure relates to the technical field of c-Met antibody drugs, specifically to a c-Met-targeted antibody-drug conjugate and applications thereof. The antibody-drug conjugate of the present disclosure comprises an antibody conjugated with one or more therapeutic agents or antigen-binding fragments of the antibody, is able to effectively inhibit the growth of a tumor tissue, provides a significant inhibitory effect with respect to c-Met-positive cancer, and has excellent safety.
    Type: Application
    Filed: August 31, 2021
    Publication date: May 23, 2024
    Inventors: Jianmin FANG, Changjiang HUANG, Xuejing YAO, Wenting LUO
  • Patent number: 11629180
    Abstract: The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: April 18, 2023
    Assignee: Remegen Co., Ltd.
    Inventors: Jing Jiang, Jianmin Fang, Xuejing Luan, Xuejing Yao, Ling Wang
  • Publication number: 20220133633
    Abstract: Disclosed is a pharmaceutical formulation containing a mixture of a non-reducing sugar, a TACI-Fc fusion protein and at least one amino acid. The pharmaceutical formulation has the characteristics of reducing particulate matter, reducing aggregate formation, improving the stability, improving the appearance of a freeze-dried powder, etc.
    Type: Application
    Filed: December 9, 2020
    Publication date: May 5, 2022
    Inventors: Qiaoyu Xu, Zhuanglin Li, Xuejing Yao, Jianmin Fang
  • Publication number: 20210324039
    Abstract: The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like.
    Type: Application
    Filed: December 4, 2019
    Publication date: October 21, 2021
    Inventors: Jing Jiang, Jianmin Fang, Xuejing Luan, Xuejing Yao, Ling Wang
  • Publication number: 20210154314
    Abstract: The invention relates to a pharmaceutical formulation comprising a mixture of a non-reducing sugar, a recombinant humanized anti-Her2 monoclonal antibody-MMAE conjugate, and a surfactant. The pharmaceutical formulation has characteristics of reduced particulate matter, reduced aggregates, improved stability of the conjugate, improved appearance of the lyophilized powders and the like.
    Type: Application
    Filed: March 25, 2020
    Publication date: May 27, 2021
    Inventors: Zhuanglin Li, Qiaoyu Xu, Xuejing Yao, Qianjing Bao, Jianmin Fang
  • Publication number: 20200138968
    Abstract: The present disclosure relates to a process for preparing an intermediate of antibody-drug conjugate. Compared with the conventional art, the process for preparing an intermediate of the antibody-drug conjugate provided by the present disclosure significantly reduces the feed loss for drug moiety, such as MMAD/MMAE or MMAF, etc., as drug moiety is involved in the last step of the reaction, thereby effectively reducing production costs, as well as increasing production efficiency. In addition, the process provided by the present disclosure is simple, environmentally friendly and suitable for large-scale industrialization.
    Type: Application
    Filed: May 20, 2019
    Publication date: May 7, 2020
    Inventors: Changjiang HUANG, Hui YE, Xuejing YAO, Haohua JIE, Shizhong ZHAI, Jianmin FANG
  • Patent number: 10087260
    Abstract: Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 2, 2018
    Assignee: REMEGEN, LTD.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Xuejing Yao, Hongwen Li, Qiaoyu Xu, Zhuanglin Li
  • Publication number: 20160304621
    Abstract: Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 20, 2016
    Applicant: REMEGEN, LTD.
    Inventors: Jianmin FANG, Changjiang HUANG, Jing JIANG, Xuejing YAO, Hongwen LI, Qiaoyu XU